Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07078955 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Dose Regimen Study of BRM421 Ophthalmic Solution in Patients With Dry Eye Disease

StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Sep 2026 to Nov 2026
    • Start date: Nov 2025 to Dec 2025
    • Interventions: BRM421 Ophthalmic Solution, 0.03% (Drug), BRM421 Ophthalmic Solution, 0.06% (Drug), Vehicle Ophthalmic Solution (Drug) to Artificial Tear (Drug), BRM421 Ophthalmic Solution, 0.03% (Drug), BRM421 Ophthalmic Solution, 0.06% (Drug)
    • Eligibility criteria shortened, about 31 words
    v4
  2. Study title shortened, about 2 wordsv3
  3. Study title shortened, about 13 wordsv2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To evaluate the safety and efficacy of BRM421 Ophthalmic Solution compared to artificial tear for treatment of the signs and symptoms of dry eye disease (DED)
Trial Details
NCT Number NCT07078955
Lead Sponsor BRIM Biotechnology Inc.
Conditions
(from sponsor)		 Dry Eye Disease (DED), Keratoconjunctivitis Sicca
Related terms Dry Eye Syndromes, Keratoconjunctivitis Sicca
Enrollment 99 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov